BridgeBio Pharma (NASDAQ: BBIO) stock jumped 76% on Monday. BBIO stock was up on the turnaround in their testing of a heart drug - one that had done exceedingly badly earlier - and the news that they'd soon be filing to try and gain FDA authorisation. Of course, the news of filing doesn't mean that the licence will be granted - but no one does file before they think they will gain the necessary permissions. The lesson for us here as investors is how important that FDA authorisation is to anyone in the pharma or drug, even medical tech, business. The authorisation from the bureaucracy is a vital part of any business plan - so that even the news that a filing for the authorisation is being planned leads to this 76% stock price rise.
BridgeBio: ”BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy,” This first part of that could describe all sorts of people. It's that last which is important here. That drug had terrible test results at first: “18 months ago the first part of the pivotal trial of Bridgebio's ATTR cardiomyopathy therapy acoramidis failed spectacularly. Today the second main readout from the study gave the company the win it so desperately needed,” And thus the BBIO stock price rise:

BridgeBio Pharma stock price from NASDAQ
Of course, what we really want to know here is well, what happens next? BridgeBio has some (with rounding) $400 million in cash and equivalents. It also has losses of $125 million or so a quarter. Well, that's just what it costs to run a large research and testing organisation. Net income is about zero (couple of million or so).
Well, a runway of perhaps 12 months, 9 months to leave a bit of margin. A drug probably entering the FDA approval process by the end of the year - so revenue's not going to arrive before the end of the runway. Plus a stock price up by 70% and more? We'd suggest that a very likely occurrence is a stock issuance in order to top up those fiscal resources. We'd not guarantee that this is going to happen but we would predict it.
Certainly, we'd predict that the higher BBIO stock goes then the more likely a stock issuance which would likely bring it back down again. For that's just how the finances of development stage pharma companies work.